Dmytro Kharkov

Syndax Pharmaceuticals secures 23 ASH25 presentations highlighting research progress

Syndax Pharmaceuticals secures 23 ASH25 presentations highlighting research progress
@Syndax: Syndax secures 23 ASH25 slots

Syndax Pharmaceuticals has announced a significant milestone in its research efforts with the acceptance of 23 abstracts, including six oral presentations, for the upcoming 67th American Society of Hematology (ASH25) Annual Meeting.

This development underscores the ongoing promise and potential impact of Syndax's research activities. The diverse range of topics covered by these presentations is set to reveal valuable insights into the field of hematology. The ASH Annual Meeting is a prestigious event that attracts global leaders in blood disease research, making this acceptance an important achievement for Syndax Pharmaceuticals.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.